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Seroprevalence of hepatitis B virus
infection, anti-HCV antibodies and HIV and
knowledge among people who use drugs
attending methadone therapy clinic in
Tanzania; a cross-sectional study
Semvua B. Kilonzo1,2* , Daniel W. Gunda1,2, David C. Majinge1,2, Hyasinta Jaka1,2, Paulina M. Manyiri1,2,
Fredrick Kalokola1,2, Grahame Mtui3, Elichilia R. Shao4, Fatma A. Bakshi5 and Alex Stephano1
Abstract
Background: Methadone therapy clinics have been recently introduced in Tanzania, aiming at reducing risk
behaviors and infection rates of viral hepatitis and HIV among people who use drugs. The objective of this study
was to estimate the prevalence, associated factors and knowledge level of these conditions among people who
use drugs attending a methadone clinic in Tanzania.
Methods: We enrolled 253 People who using drugs receiving Methadone therapy. Clinical data was retrospectively
collected from the medical records and face-to face interviews were conducted to determine the behavioral risk
factors and respondents’ knowledge on viral hepatitis and HIV.
Results: An overall seroprevalence of viral hepatitis (either hepatitis B surface antigen or anti-hepatitis C virus) was
6.3%, while that of hepatitis B virus mono infection was 3.5% and anti-hepatitis C antibodies was 3.5%.
Seroprevalence of HIV was 12.6%. Viral hepatitis was strongly predicted by advanced age (> 35 years) (p = 0.02) and
staying at Kirumba area (p = 0.004), and HIV infection was predicted by increased age (> 37 years) (p = 0.04) and
female sex (p < 0.001). Regarding the knowledge of viral hepatitis, majority of the respondents were unaware of the
transmission methods and availability of hepatitis B virus vaccines and only 17% were classified as well informed
(provided ≥4 correct answers out of 7 questions). Good knowledge was highly predicted by higher education level
of the individual (p = 0.001).
Conclusions: Despite the efforts to curb viral hepatitis and HIV infections through Methadone clinics, infection
rates among people who use drugs are still high and the general knowledge on preventive measures is
inadequate.
Keywords: Viral hepatitis, HIV, People who use drugs, Tanzania
© The Author(s). 2021 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License,
which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give
appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if
changes were made. The images or other third party material in this article are included in the article's Creative Commons
licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons
licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain
permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the
data made available in this article, unless otherwise stated in a credit line to the data.
* Correspondence: sekipcb@yahoo.com
1Department of Medicine, Catholic University of Health and Allied Sciences,
P.O Box 1464, Mwanza, Tanzania
2Department of Medicine, Bugando Medical Center, P.O Box 1370, Mwanza,
Tanzania
Full list of author information is available at the end of the article
Kilonzo et al. BMC Infectious Diseases          (2021) 21:699 
https://doi.org/10.1186/s12879-021-06393-0
Background
Viral hepatitis (VH) is an increasing global public health
problem and various hepatitis viruses (A, B, C, D, and E
viruses) have been implicated. While Hepatitis A (HAV)
and hepatitis E (HEV) are frequent causes of acute spor-
adic infections and outbreaks, Hepatitis B virus (HBV)
and hepatitis C virus (HCV), usually lead to chronic in-
fections that can complicate to liver cirrhosis or hepato-
cellular carcinoma if un-intervened. Globally, about 257
million people are living with chronic hepatitis B (CHB)
and 71 million people with hepatitis C. In sub-Saharan
Africa (SSA), around 60 million people are estimated to
have CHB and 10 million more to have chronic HCV in-
fection [1]. Additionally, Africa is an epicenter for Hu-
man immunodeficiency virus (HIV), where nearly 25
million people are currently living with the disease [2].
In Tanzania, the overall seroprevalence of hepatitis B
surface antigen (HBsAg), hepatitis C antibody (anti-
HCV), and HIV infection is estimated to be 4.1, 2.0, and
4.7% respectively in the general community [3]. While
the rate of HIV infection in the country has decreased
from previous estimates [4], studies among different
sub-populations suggest an escalating rate of viral hepa-
titis. For instance, among people who inject drugs
(PWID), HBsAg seroprevalence of 7.8% has been re-
ported recently [5], which is over 3-fold of the earlier re-
ports in 2006 [6]. The seroprevalence of anti-HCV in
this subgroup of people varies from 16.2–50.2% [5, 7, 8].
People who inject drugs are at increased risk of acquir-
ing HIV, HBV, and HCV infections due to associated
risk-related injecting behaviors and risky sexual prac-
tices. Following a surge of HIV and other blood-borne
infections among PWID, the first Methadone therapy
clinic (MTC) was established in Tanzania in 2011, and
currently there are 6 functional clinics (three in Dar es
Salaam, one in Mbeya, one in Dodoma and one in
Mwanza). Mwanza clinic, where this study was done,
was first opened in 2018. At present in these clinics,
Methadone, which is Opioid receptor agonist, is the only
used drug for the management of Opioid use disorders.
However, the plans are underway to include other avail-
able approaches in the future like use of new adrenergic
agonists such as Buprenorphine, use of Opioid receptor
antagonists such as Naltrexone, implementation of harm
reduction programs, and comprehensive HIV, Tubercu-
losis& hepatitis services. Around 300,000 people are esti-
mated to be abusing narcotic drugs in the country, and
among them, 30,000 use injectable drugs. Only 20% of
them have been enrolled in MTCs [9]. Mwanza city,
which is the second largest in the country is estimated
to constitute 300 PWID [10].
The majority of studies regarding the status of this
population have been based in Dar es Salaam. The aims
of this study, therefore, were to estimate the
seroprevalence of HBsAg, anti-HCV, and HIV and to as-
sess the knowledge regarding viral hepatitis and HIV
among PWID attending MTC at Sekou Toure Regional
Referral hospital (STRRH) in Mwanza.
Methods
Study design and setting
This was a cross-sectional study among PWID attending
MTC in Mwanza, Tanzania from September 2019 to
May 2020. A convenient sampling was done, and all 256
registered participants at Sekou Toure MTC were
included.
Data collection
The included patients had attended MTC for at least 2
weeks. The patients’ files were reviewed where socio-
demographic information, latest status of HBsAg, HCV
antibodies, and HIV were recorded. These tests are usu-
ally done 6 monthly according to the guiding standard
operating procedures [11]. Hepatitis B test was done by
rapid HBsAg (Meriscreen HBsAg, Gujarat India) and
hepatitis C was tested using rapid test for HCV antibody
(Camp medica group, Bucharest Romania) according to
the manufacturer’s instructions. HIV tests were per-
formed according to the Tanzanian national guidelines
for HIV testing [12].
A specific questionnaire was developed for this study
where face-to-face interviews were conducted. Series of
closed ended questions were asked regarding the types,
route and duration of drug used behavioral risk factors
for viral hepatitis, and HBV vaccination status. Also,
seven more questions were asked regarding the respon-
dents’ knowledge on the transmission of viral hepatitis
and availability of HBV vaccine to PWID in the public
health facilities. Primary outcomes were the prevalences
of VH and HIV, and the knowledge level regarding
HBV. Individuals were considered to have good know-
ledge when they answered more than 3 correct answers
of seven questions.
Data analysis
Data were computerized using Epi data version 3.1 and
STATA 13 (Stata Corp LP, college station, TX) was used
for analysis. Continuous variables were summarized as
medians with interquartile range (IQR) and categorical
variables as proportions with percentages. The compari-
sons between the baseline characteristics of PWID in re-
lation to the presence of HBV, HCV or HIV were done
using the non-parametric Mann Whitney U test. To de-
termine the factors that were independently associated
with HBV, HCV, and HIV infections, the simple binary
logistic regression was first performed, and the variables
with p < 0.2 were included in the multivariate model.
The level of significance was set at p < 0.05. The
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goodness of fit for the final model was assessed subse-
quently. The sensitivity and specificity of independent
factors in the final model were also assessed to deter-
mine their discriminative ability. The Receiver Operating
Characteristic (ROC) curves were used according to
Hanley and McNeil’s method to determine the cut
points with the best sensitivity and specificity for con-
tinuous variables which were reported as proportions
with 95% Confidence interval (CI).
Ethical clearance
The permission to conduct and publish the findings
from this study was sought from the Catholic University
of Health And Allied Sciences (CUHAS) /Bugando Med-
ical Centre (BMC) joint ethical committee with an eth-
ical clearance certificate number CREC/1399/2019. The
patients’ information was handled by the researcher
alone and their identifiers including names and registra-
tion numbers were not included in the final analysis to
further conserve confidentiality.
Results
Characteristics and demographics of the study
participants
We recruited a total of 256 PWUD attending MTC at
STRRH from September 2019 to May 2020. Three cli-
ents were excluded from the study; two did not consent
and one had missing data, leaving 253 for analysis. Out
of 253 PWUD, 9 were infected with HBV and 9 were
positive for anti-HCV antibodies. Coexistence of HBsAg
and anti-HCV antibodies was detected in 2 subjects. The
seroprevalence of HIV was 32 (12.6%). Coexistence of
HIV and anti-HCV was detected in 2 subjects. None of
the clients was found to have HIV-HBV co infection.
Demographics and characteristics of the patients with
HBV infection, anti-HCV positivity, and HIV infection
have been illustrated in Table 1.
People who injected drugs were predominantly males
with a female: male ratio of 1:10. None of the females
were found to be either positive for HBsAg or anti-HCV.
Regarding the HIV infection, the females were more
likely to be positive compared to their males counter-
parts (37.5% vs. 4.9%, p < 0.001). The age group of 25 to
30 years comprised the majority (37.9%) of the study
population, while the elderly group (> 50 years) em-
braced the minority (0.8%). Significantly higher fre-
quency of both, HBV infection and anti-HCV occurred
in the age group of 36 to 40 years (p = 0.01 for both).
Also, there was a slight trend of higher HIV infection
rate towards advanced age (41–45 years), though it was
not statistically significant (p = 0.07). In the younger
population (< 30 years), occurrences of HBV infection
and anti-HCV were insignificant.
HIV infection was significantly higher among the mar-
ried or cohabiting PWUD (62.5% vs. 40.7%, p = 0.02). No
statistical difference was observed between the marital
status and HBV infection and anti-HCV seropositivity.
Regarding Opioid use, nearly 30% reported being using
additional drugs. More than one-half of the study partic-
ipants were using the injection method, and out of these,
124 (79.5%) were both injecting and snorting and
32(20.5%) were injecting only. About 30% of all drug
users had used the Opioid for more than 10 years, and
only 39(15.4%) had used for< 5 years. The types of drugs
used, route and duration were all insignificant regarding
the occurrence of HBV, HCV, or HIV. Surprisingly,
none of the client have had received vaccine for HBV in-
fection (Table 1).
Predictors of viral hepatitis and HIV
Tables 2 and 3 respectively illustrate the predictors of
viral hepatitis (HBsAg or anti-HCV) and HIV infection
by multivariable logistic regression. Age above 35 years
(p = 0.02) and Staying in Kirumba area (p = 0.004) were
the only factors that were independently associated with
viral hepatitis while female sex (p < 0.001), and age above
37 years (p = 0.04) strongly predicted HIV positivity.
Hosmer-Lemeshow tests for goodness of fit did not indi-
cate evidence of gross lack of fit with the area under the
ROC curve of 0.83 for viral hepatitis (Fig. 1) and 0.80 for
HIV (Fig. 2).
Knowledge of viral hepatitis
Majority of the responders didn’t know that viral hepa-
titis could be transmitted by sexual intercourse (92.9%),
body fluids exposure (90.1%), blood exposure (84.2%),
and sharing of instruments like needles (84.2%). Finally,
only 51(20.1%) knew about the availability of HBV vac-
cines. The details have been shown in Table 4.
Forty-two, 16.6% (95%CI: 12.2–21.8) individuals were
classified as well informed (4–7 correct answers) and
83.4% (95%CI: 78.2–87.8) were less informed (0–3 cor-
rect answers). Only 2, 0.8% (95%CI: 0.09–2.8) individuals
responded correctly to all questions and 66.4% (95%CI:
60.6–72.6) reported incorrect answers to all questions.
In multivariate logistic regression analysis, the good
knowledge of viral hepatitis was found to be significantly
predicted by higher education level of the individual
(p = 0.001) (Table 5).
Discussion
This cross-sectional study was conducted to establish
the prevalence of viral hepatitis and HIV, and to deter-
mine the knowledge level among PWUD. We have re-
ported a high seroprevalence of viral hepatitis (6.3%) and
HIV (12.6%) in this population. We have also demon-
strated that the occurrence of viral hepatitis is predicted
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by age > 35 and injection route of drug use, while that of
HIV is highly predicted by age > 37 years and female sex.
The general knowledge regarding to viral hepatitis is
modest.
Seroprevalence of anti-HCV (3.5%) and HIV (12.6%)
in this study were found to be higher than the general
population in the country which is estimated to be 2 and
4.7% for HCV and HIV respectively [3, 4]. The same
trend of results has been previously reported in Dar es
Salaam, Tanzania where significantly higher seropreva-
lence of anti-HCV (57%) and HIV (40%) compared to
the general population among PWUD attending MTC
were reported [13]. These results support the notion that
PWUD forms an important key population for HCV and
HIV infections. The vast difference of rates between the
later study and ours might be explained by the reasons
that the later study was conducted from 2011 to 2013,
immediately after commencement of MTC and harm re-
duction program in the country; therefore many clients
were unaware of infection protection methods. Also, dif-
ferent study sites have different infection rates due to
the urbanization effect which is a major factor for viral
transmission [14–16]. This effect has further been ob-
served in the current study where the Kirumba area,
Table 1 Baseline characteristics of PWUD in relation to the presence of HBV, anti-HCV and HIV (n = 253)














HIV + (n =
32)




Sex a a <
0.001
Male 230 (90.9) 9 (3.9) 221(90.6) 9(3.9) 221(90.6) 20(62.5) 210(95.0)
Female 23(9.1) 0 23(9.4) 0 23(9.4) 12(37.5) 11(4.9)
Age groups
18–24 32 (12.7) 0 32(13.1) a 0 32(13.1) a 6(18.8) 26(11.8) 0.27
25–30 96 (37.9) 0 96(36.3) a 2(22.1) 94(38.5) 0.32 3(9.4) 93(42.1) <
0.001
31–35 51 (20.2) 3(33.3) 48(19.7) 0.32 2(22.2) 49(20.1) 0.88 7(21.9) 44(19.9) 0.79
36–40 38(15.0) 4(44.4) 34(13.9) 0.01 4(14.4) 34(13.9) 0.01 8(25.0) 30(13.6) 0.09
41–45 25(9.9) 1(11.1) 24(9.8) 0.89 1(11.1) 24(9.8) 0.89 6(18.8) 19(8.6) 0.07
46–50 9(3.6) 1(11.1) 8(3.3) 0.21 0 9(3.7) a 2(6.3) 7(3.2) 0.38
> 50 2(0.8) 0 2(0.8) a 0 2(0.8) a 0 2(0.9) a
Marital 0.51 0.95 0.02
Single 143(56.5) 4(2.8) 139(56.9) 5(55.6) 138(56.6) 12(37.5) 131(59.3)
Married/cohabiting 110(43.5) 5(55.6) 105(43.0) 0.46 4(44.4) 106(43.4) 20(62.5) 90(40.7)
Education 0.65 0.29 0.08
Primary or below 180 (71.2) 7(77.8) 173(70.9) 5(55.6) 175(71.7) 27(84.4) 153(69.2)
Secondary and
above
73 (28.9) 2(22.2) 71(29.1) 4(44.4) 69(28.3) 5(15.6) 68(30.8)
Drug history
Types of drugs 0.78 0.78 0.88
Opioids only 179(70.8) 6(66.7) 173(70.9) 6(66.7) 173(70.9) 23(71.9) 156(70.6)
Opioids + other
drugs
74(29.3) 3(33.3) 71(29.1) 3(33.3) 71(29.1) 9(28.1) 65(29.4)
Route
Injection only 32(12.7) 3(33.3) 29(11.9) 0.05 2(22.2) 30(12.3) 0.58 3(9.4) 29(13.1) 0.55
Snorting only 97(38.3) 0 97(39.8) a 2(22.2) 95(38.9) 0.38 9(28.1) 88(39.8) 0.20
Both 124(49.0) 6(66.7) 118(48.4) 0.28 5(55.6) 119(48.8) 0.69 20(62.5) 104(47.1) 0.10
Duration of drug use
< 5 years 39(15.4) 0 39(15.9) a 0 39(15.9) a 3(9.4) 36(16.3) 0.56
5–10 years 136(53.8) 4(44.4) 132(54.1) 0.57 4(44.4) 132(54.1) 0.56 15(46.9) 121(54.8) 0.40
> 10 years 78(30.8) 5(55.6) 73(29.9) 0.60 5(55.6) 73(29.9) 0.10 14(43.8) 64(28.9) 0.09
a Not computed because of zero observation
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which is in the Mwanza city center, comprised signifi-
cantly more cases of viral hepatitis. Regarding HBV in-
fection, the prevalence obtained from this study (3.5%) is
lower than that of the general population in the country,
which is estimated to be 4.1% [3]. To date, there is no
published data on the prevalence of HBV infection
among PWUD enrolled in MTC. However, the magni-
tude of HBV infection among PWUD who are not en-
rolled in MTC is higher than that of the general
population in the country [5, 8] and globally [17]. There-
fore, our findings suggest the positive association be-
tween MTC attendance and low rates of VH in the
country. Methadone replacement therapy in PWUD has
been found to be effective intervention to prevent
transmission of VH [18] and HIV [19], to reduce
injecting-related risk behaviors [20], and to improve
health-related quality of life [21], healthcare utility,
utilization and expenditure [19]. Nevertheless, this
promising upshot should not enervate the efforts to scale
up other available modalities of management of Opioid
use disorders like Opioid receptors antagonists and
harm reduction that are currently inexplicit in the coun-
try, as combined prevention measures have been shown
to be more effective that any measure alone [22].
We found a clear variation of age and gender profiles
of PWUD and their association with VH and HIV infec-
tions. More than 90% of the studied population was
males and one-half were below 30 years old. This is in
Table 2 Predictors of Viral Hepatitis
HBsAg /anti-HCV positive
Crude Odd Ratio(95%CI) P value Adjusted Odds Ratio (95% CI) P value
Age > 35 2.3(0.6–8.8) 0.001 4.5(1.2–16.9) 0.02
Address
Kirumba 4.3 (1.5–11.9) 0.006 5.1(1.7–15.3) 0.004
Sahara 0.7(0.1–5.4) 0.70 α
Bugarika 2.5(0.5–11.9) 0.27 α
Igogo 1.1(0.1–9.4) 0.89 α
Married (compared to single) 1.7(0.6–4.8) 0.29 α
Low education level 10.4(0.1–2.8) 0.33 α
Having multiple sexual partners 1.8(0.6–5.8) 0.32 α
Using drugs> 9 years 3.8(1.2–12.0) 0.03 2.1(0.5–8.6) 0.29
Use of multiple drugs 1.2(0.3–5.0) 0.78 α
Route of drug use, injection 3.5(1.1–10.9) 0.02 3.2(0.9–10.8) 0.06
Key: CI Confidence interval
α Not included in multivariate analysis
Table 3 Predictors of HIV
HIV
Crude Odds Ratio (95%CI) P value Adjusted Odds Ratio (95%CI) P value
Female sex 11.5(4.5–29.3) < 0.001 78.2(8.3–741.1) < 0.001
Age > 37 3.2(1.5–6.9) 0.003 4.5(1.7–11.6) 0.002
Low education level 2.4(0.9–6.5) 0.09 1.2(0.4–3.4) 0.78
Address
Kirumba 1.6(0.7–3.6) 0.29 α
Igoma 1.4(0.4–6.9) 0.45 α
Bugarika 1.1(0.2–4.9) 0.93 α
Marital (Married) 2.4(1.1–5.2) 0.02 1.5(0.6–3.7) 0.38
Sex trade 3.7(1.3–10.5) 0.01 0.1(0.01–1.2) 0.07
Men who sex with men 1.3(0.3–6.3) 0.70 α
Multiple sexual partners 1.6(0.7–3.5) 0.28 α
Tatoo 0.9(0.4–2.1) 0.88 α
Key: CI Confidence interval
α Not included in multivariate analysis
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line with a recent large meta-analysis review where it
was reported that in low and mid-income countries
PWUD were exclusively males and young adults while
more aging with increasing women population was evi-
denced in high-income countries [17]. Furthermore, it
has been previously reported that the occurrence of VH
among PWUD increases with age, with no effect on gen-
der despite the males’ preponderances [5, 7, 8], while
that of HIV infection is strongly predicted by female sex
[23, 24]. Similar findings have been observed in this
study. Tanzania is an endemic country for HBV infec-
tion and the commonest (> 90%) mode of transmission
is perinatally through mother-to-child, with the trivial
horizontal transmission in the general population. Most
of the people born before the year 2002 when the vac-
cine against HBV was introduced in the country, remain
unvaccinated to date [3], and due to unavailability of
HBV Immunoglobulin, children born to HBsAg positive
mothers, are likely to be habitually infected. Thus, by
having insignificant cases of HBV infection among the
young adults that are mostly unvaccinated indicates that
transmission is conspicuously horizontal among PWUD
and likely driven by riskier substance use behaviors in
this group of people.
To the best of our knowledge, this is the first study to
describe knowledge of VH among PWUD that are en-
rolled in MTC in the country. The present study dem-
onstrates significant deficits in knowledge about viral
Fig. 1 Test for goodness of fit for multivariate logistic model for viral hepatitis
Fig. 2 Test for goodness of fit for multivariate logistic model for HIV
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hepatitis transmission and the availability of HBV vac-
cine in the public health service facilities. Only 17% of
the respondents were classified as well informed, and <
1% responded correctly to all questions. Furthermore,
none of the clients had ever received the HBV vaccine.
These findings are similar to previously reported data
where lesser-educated responders and those who were
negative for VH were likely to score low on VH know-
ledge [25, 26]. Some education (above primary school)
strongly predicted good knowledge of VH in the index
study while more than two-fold of respondents with
good knowledge were observed among VH seropositive
compared to their seronegatives counterparts. In the re-
cent National Guidelines for Comprehensive Manage-
ment of Opioid use disorder [27], it has been
recommended that all PWUD attending MTC should re-
ceive comprehensive health education on the prevention
of VH and HIV. Those who have been infected, should
be linked immediately to the relevant care services while
those who have not been infected by HBV, should be
vaccinated. Despite this clear guidance, surprisingly none
of the clients had ever received the HBV vaccine in the
index study. HBV vaccination status among PWUD in
the country has never been reported before. The previ-
ous studies regarding HBV vaccination statuses in the
country mainly focused on the health care workers [28–
30] which have also been reported to be unsatisfactory.
Based on the previous reports [28], lack of publicity and
access to HBV vaccination seems to be the major stum-
bling blocks to increased coverage.. These findings
underscore the importance of intensifying health educa-
tion service and improving access to HBV vaccination in
this group. One major limitation for this study is inabil-
ity to validate the information given by the clients.
Conclusions
The current study has conclusively demonstrated that
VH and HIV have substantial magnitude among PWUD
attending MTC in Mwanza, Tanzania, and the rate in-
creases significantly with age and geographical location
for VH, and female gender for HIV. We have also re-
vealed insubstantial knowledge of VH in this population
with negligible uptake of the HBV vaccine. These find-
ings which are rare in the country are crucial as they do
not only provide important statistics among PWUD but
also feature important policy inference on tailoring com-
prehensive prevention programs and early intervention
strategies to the risky-youth population. Moreover, our
findings inform the government and other stakeholders
the discrepancies in the service provision systems that
Table 4 Knowledge of PWUD about viral hepatitis (n = 242)
Items n = 253 %
Transmission of viral hepatitis by sexual intercourse
YES 18 7.1
NO 235 92.9




Contaminated blood as a vehicle for viral hepatitis transmission
YES 40 15.8
NO 213 84.2
Transmission of viral hepatitis by sharing contaminated instruments,
such as razors, toothbrushes or needles
YES 40 15.8
NO 213 84.2
A neonate can get viral hepatitis infection from an infected mother
YES 44 17.4
NO 208 82.2
Tattoo or piercing as a potential source for viral hepatitis infection
YES 45 17.8
NO 208 82.2




Table 5 Predictors of good knowledge about viral Hepatitis among IVDU
Variable Knowledge Score cOR (95%CI) P value aOR (95%CI) P value
Good knowledge (n = 42) Poor knowledge (n = 211)
Sex (Male ref. female) 39(92.8) 191(90.5) 1.4(0.4–4.8) 0.63 α
Age (years) 31(28–37) 30(26–37) 1.0(0.9–1.1) 0.57 α
Higher education level 26(61.9) 47(22.3) 5.7(2.8–11.4) < 0.001 5.8(2.9–11.9) < 0.001
HIV positive 5(11.9) 29(12.6) 0.9(0.3–2.5) 0.87 α
HBV positive 3(7.1) 6(2.8) 2.6(0.6–10.5) 0.19 2.6(0.3–26.5) 0.42
Anti-HCV positive 2(4.8) 7(3.3) 1.4(0.3–7.3) 0.65 α
Any viral hepatitis 5(11.9) 11(5.2) 2.4(0.8–7.5) 0.11 1.4(0.2–8.2) 0.73
Key: αNot included in multivariate analysis
Good knowledge: 4–7 correct answers; Poor knowledge; 0–3 correct answers; cOR Crude Odds Ratio, aOR Adjusted Odds Ratio, CI Confidence interval
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commenced nearly 10 years ago in the country. Finally,
these findings might not be generalized hence they war-
rant a countrywide survey to all established MTCs for
their efficiency. We recommend a more focused ap-
proach of different community programs dealing with
PWUD to high-risk groups and close monitoring and
enriching available MTCs in the country to meet the de-
sired goals.
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